This is the goal which Neurizon Therapeutics Ltd – the company formerly known as PharmAust – is pursuing through development ...
Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...
Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ...
ZTE Corporation (0763.HK / 000063.SZ), a global leading provider of integrated information and communication technology solutions, has debuted the industry's first AI-powered full-stack FWA solution, ...
While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...
A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...
ASX healthcare stocks underperform, but optimism grows as Uscom, Respiri, Hitiq report mixed results and Artrya, Nyrada make ...
Spark Plus, an Asia-Pacific corporate advisory firm, puts a target price of 69.6 cents on Neurizon – a 225% upside to its ...
Bitte entschuldigen Sie den Fehler. Sollte dieser Fehler erneut auftreten, kontaktieren Sie bitte unseren Kundeservice per E-Mail.
14d
Clinical-stage biotech Neurizon Therapeutics – formerly PharmAust – made significant strides advancing its treatments for neurodegenerative diseases during the September 2024 quarter.
Other recent examples extend to Neurizon Therapeutics, a neurodegenerative medical company taking the fight to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback